Date: October 11, 2022
Time: 5:30 - 8:00 pm PDT
Location: Mission Inn Hotel & Spa, 3649 Mission Inn Ave., Riverside, CA 92501
SNMMI has applied for 1.5 hours of CE Credit for this in-person event.
Please note that seating is limited and registration will be available on a first-come, first-served basis.
Dinner is Served
Several new radiopharmaceuticals are now being used in both large academic and small practice settings to stage and identify local and metastatic prostate cancer, including the recently approved Ga-68 PSMA-11 and 18F-DCFPyL. In addition, the FDA in March approved Lu 177 vipivotide tetraxetan to treat PSMA-positive metastatic castration-resistant prostate cancer. Given these new advancements in diagnosis and treatment, how does one navigate the changing landscape to provide the best outcomes for the patient?
6:30 - 6:35 pm
Welcome and Introductions
Frankis Almaguel, MD, PhD
6:35 - 6:55 pm
Nuclear Medicine Perspective
Frankis Almaguel, MD, PhD, Director, Molecular Imaging and Therapeutics Program, Loma Linda University Cancer Center
6:55 - 7:15 pm
Eric Schaefer, MD, Medical Oncologist/Hematologist, Highlands Oncology Group, Fayetteville, AR
7:15 - 7:35 pm
Radiation Oncology Perspective
Joseph Kang, MD, Radiation Oncologist, Loma Linda Cancer Center
7:35 - 7:45 pm
7:45 - 8:00 pm
Q&A and Panel Discussion
Please note: SNMMI is committed to ensuring that appropriate and necessary health and safety protocols will be in place for this event. We will follow all Centers for Disease Control and Prevention (CDC) safety protocols and recommendations and will comply with all federal, state, and local regulations in force at the time of the event.
CE Credit applications for physicians, pharmacists, and technologists are pending. Check back for updates regarding CE Credit status.
This event is supported through a medical education grant from Lantheus Medical Imaging.